StrokeNCT03590314
Upper Limb Training Modalities in Patients With Stroke
A study testing Experimental group - robot assisted arm training (Armotion®) in people with Stroke, run by Universita di Verona at 1 site in Italy.
Trial summary
To date, evidence of the effects of robotic training combined with OnabotulinumtoxinA focal treatment for spasticity is limited. The objective of this study were to compare the effects of robotic training against conventional rehabilitation on functional recovery, strength and spasticity, in stroke patients who… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Stroke
- What is being tested?
- Experimental group - robot assisted arm training (Armotion®)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteItaly
- Study dates
- Jan 2017to Jul 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- age > 18 years;
- diagnosis of ischemic or hemorrhagic first-ever stroke as documented by a computerized tomography scan or magnetic resonance imaging;
- at least 6 months since stroke;
- Modified Ashworth Scale (MAS) score (shoulder and elbow) ≤ 3 and ≥1+;
- BoNT injection within the previous 12 weeks of at least one of muscles of the affected upper limb;
- Mini-Mental State Examination (MMSE) score ≥24
- Trunk Control Test score = 100/100.
Who cannot join
- any type of rehabilitation intervention in the 3 months prior to recruitment;
- bilateral cerebrovascular lesion;
- severe neuropsychologic impairment (global aphasia, severe attention deficit or neglect);
- concomitant orthopedic disorders.
Trial locations and contacts
1 site in 1 country.
Italy1 site
Azienta Ospedaliera, SSO Rehabilitation Unit, Verona
Verona, Italy, Verona, 37134
About this study
Official title: Combined Robot-assisted Upper Limb Training and Botulinum Toxin Treatment for Upper Limb Function and Spasticity: a Randomized Controlled Single-blinded Trial in 32 Chronic Stroke Patients.
To date, evidence of the effects of robotic training combined with OnabotulinumtoxinA focal treatment for spasticity is limited. The objective of this study were to compare the effects of robotic training against conventional rehabilitation on functional recovery, strength and spasticity, in stroke patients who underwent OnabotulinumtoxinA focal treatment for spasticity. We performed a single-blind, randomized, controlled trial involving 24 outpatients with diagnoses of stroke, divided in two groups (experimental and control group). Experimental group received specific robotic training for the upper limb with the device Armotion/Motore (Reha Technology AG, Olten, Switzerland). Our primary outcome was Fugl-Meyer Assessment Motor Scale (FMA). Secondary outcome were Action Research Arm Test (ARAT), Modified Ashworth Scale (MAS), Medical Research Council Scale (MRC) and surface Electromyography (EMG). 14 healthy age-matched controls underwent one session of sEMG acquisition to collect normative data.
Read the detailed description
This single-blind RCT with two parallel group was conducted according to the tenets of the Declaration of Helsinki, the guidelines for Good Clinical practice, and the Consolidated Standards of Reporting Trials (CONSORT).
Target population was chronic post-stroke patients who attend to the Neurorehabilitation Unit (AOUI Verona) where they were assessed for eligibility.
Who satisfied inclusion and exclusion criteria were randomly allocated in one of two groups, experimental group ad control group. Each patient, underwent BoNT injection in the paretic limb. The dose of BoNT injected into the target muscle was based on the severity of spasticity in each case. Different commercial formulations of BoNT were used according to the pharmaceutical portfolio contracts of our Hospital (Onabotulinumtoxin A, Abobotulinumtoxin A and Incobotulinumtoxin A). The dose, volume and number of injection sites were set accordingly. A Logiq ® Book XP portable ultrasound system (GE Healthcare; Chalfont St. Giles, UK) was used to inject BoNT into the target muscle.
Prior of the start of the study authors designed the experimental and the control group protocols. Two physiotherapists, one for each group carried out the rehabilitation procedures. Patients of both groups received 10 individual sessions (45 min/session, 2 sessions/week, five consecutive weeks). Treatments were performed in the rehabilitative gym of the G.B. Rossi University Hospital Neurological Rehabilitation Unit.
A subgroup of patients in the experimental group were investigated by Electromyography during the "hand-to-mouth" motor task (ARAT sub-item). The subject seated in a comfortable position on a chair with backrest, the feet resting on the floor and the knees and hips flexed at 90°. The start position consisted of the hand of the examined side lying on the distal third of the thigh. Then, the patient was asked to touch his mouth with the palm of the hand at normal speed and return to the starting position. The patient was instructed not move the head toward the hand. No other indications regarding how to move the arm for not to influence the spontaneity of the movement.
The EMG activity of 5 upper limb muscles of the affected side (deltoid scapular, deltoid clavicular, pectoralis major - clavicular head, triceps brachii, biceps brachii) was measured using pairs of self-adhesive surface electrodes. Disposable Ag-AgCl electrodes were placed according to SENIAM guidelines with an inter-electrode spacing of 0.02 m. Before electrode placement, the skin was shaved with a disposable, single-use razor and cleaned with alcohol.28 Raw EMG signals were collected using BTS FREEEMG 300 wireless surface EMG sensors (BTS spa, Milan, Italy) at a sampling rate of 1000 Hz. Raw EMG signals were processed with a customized routine developed in MATLAB environment (MathWorks, USA). The raw EMG signal was bandpass filtered at 20-450 Hz and then smoothed using a 20- ms root mean square (RMS) algorithm to obtain the envelope. Signals were recorded in three conditions: 30 s during resting position (basal), 5 s of maximal voluntary isometric contraction(MVIC), and during the hand-to-mouth task.
The "hand-to-mouth" task was divided into two sub-phases through the definition of three time-events: 1) start of the movement, 2) the moment when the hand touches the mouth and 3) return to the initial position. The first sub-phase, named "elbow flexion phase", was defined as the interval between the movement onset and the maximum elbow flexion. The second sub-phase, named "return phase", refers to the interval between the maximum elbow flexion until movement offset after returning to the starting position (Figure X). Normative data were collected from 14 healthy age-matched controls undergoing one EMGs acquisition. The time-events were determined using an accelerometer (BTS spa, Milan, Italy).
For the statistical analysis an intention to treat was used. Descriptive statistics included means, standard deviation and graphs. The Shapiro-Wilk test was used to test data distribution. Parametric or non-parametric tests were used for inferential statistics, accordingly. The T-Test for unpaired data (or the Mann-Whitney test) was used for testing between-group differences at T0 and T1. For this purpose, we computed the changes of score (Δ) between T0-T1. The T-Test for paired data (or Wilcoxon signed rank tests) was used to compare within-group changes over time. The level of significance was set p<0.05. Software statistics SPSS 20.0 (IBM SPSS Statistics for Windows, Version 20.0, Armonk, NY, USA).
- Conditions
- Stroke
- Being tested
- Experimental group - robot assisted arm training (Armotion®), Control group - conventional treatment
- Keywords
- Stroke, Upper limb, Recovery
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Experimental group - robot assisted arm training (Armotion®)Device
Also called Robot assisted treatment (Armotion®)
Passive mobilization and stretching exercises for affected upper limb (10 minutes) followed by robot-assisted exercises (35 minutes). Were selected four types of exercises contained within the Armotion® software:
- "Collect the coins"
- "Drive the car"
- "Wash the dishes"
- "Burst the balloons"
For increment the difficulty, we have varied the assisted and non-assisted modality, increasing the number of repetitions over the study period.
Control group - conventional treatmentOther
Also called Conventional treatment
Upper limb passive mobilization and stretching (10 minutes) followed by exercises (35 minutes) that incorporated single or multi-joints movements for the scapula, shoulder and elbow, performed in different positions (i.e. supine and standing position). The increase of difficulty and progression of intensity were obtained by increasing ROM, repetitions and performing movements against gravity or against slight resistance.
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Experimental | The experimental group was treated using a robot assisted arm training, Armotion (Reha Technology, Olten, Switzerland). Receives: Device: Experimental group - robot assisted arm training (Armotion®) |
| Control group | Active comparator | The control group was treated using a conventional training, without end effector robot. Receives: Other: Control group - conventional treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fugl Meyer Upper Limb Assessment scale
Evaluate functional improvements of upper limbs
Measured: Up to six weeks
Secondary outcomes (4)
Modified Ashworth Scale
Evaluate upper limb spasticity
Measured: Up to six weeks
Medical Research Council Scale
Evaluate the muscle strength
Measured: Up to six weeks
Active Range of Motion
Measure in degrees through a goniometer the shoulder, elbow and wrist joints active range of motion
Measured: Up to six weeks
UL electromyographic analysis of muscle activation
Instrumental assessment of muscle activity during a reaching task
Measured: Up to six weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2018
- Study startJan 2017
- Primary completionNov 2017
- Study completionJul 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Single-blind RCT with two parallel group
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 32 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universita di Verona
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nicola Smania, MD, Clinical Professor, Universita di Verona
- Investigators
- Nicola Smania, Professor, Principal investigator, Universita di Verona
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03590314
- Sponsor's protocol ID
- UPPER-Trial
- Status last verified
- Jul 2018
- First submitted
- 5 Jul 2018
- Last updated
- 18 Jul 2018
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Publications
Gandolfi M, Vale N, Dimitrova EK, Mazzoleni S, Battini E, Filippetti M, Picelli A, Santamato A, Gravina M, Saltuari L, Smania N. Effectiveness of Robot-Assisted Upper Limb Training on Spasticity, Function and Muscle Activity in Chronic Stroke Patients Treated With Botulinum Toxin: A Randomized Single-Blinded Controlled Trial. Front Neurol. 2019 Jan 31;10:41. doi: 10.3389/fneur.2019.00041. eCollection 2019.
PubMed 30766508
Study at a glance
From the registry record, last updated by the sponsor on 18 Jul 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Combined Robot-assisted Upper Limb Training and Botulinum Toxin Treatment for Upper Limb Function and Spasticity: a Randomized Controlled Single-blinded Trial in 32 Chronic Stroke Patients.
- ClinicalTrials.gov ID
- NCT03590314
- Acronym / sponsor ID
- UPPER-Trial
- Conditions
- Stroke
- Keywords
- Stroke, Upper limb, Recovery
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 32 participants (actual)
- Lead sponsor
- Universita di VeronaUniversity, hospital or other
- Study start
- Jan 2017
- Primary completion
- Nov 2017 (actual)
- Study completion
- Jul 2018 (actual)
- First posted
- 18 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To date, evidence of the effects of robotic training combined with OnabotulinumtoxinA focal treatment for spasticity is limited. The objective of this study were to compare the effects of robotic training against conventional rehabilitation on functional recovery, strength and spasticity, in stroke patients who underwent OnabotulinumtoxinA focal treatment for spasticity. We performed a single-blind, randomized, controlled trial involving 24 outpatients with diagnoses of stroke, divided in two groups (experimental and control group). Experimental group received specific robotic training for the upper limb with the device Armotion/Motore (Reha Technology AG, Olten, Switzerland). Our primary outcome was Fugl-Meyer Assessment Motor Scale (FMA). Secondary outcome were Action Research Arm Test (ARAT), Modified Ashworth Scale (MAS), Medical Research Council Scale (MRC) and surface Electromyography (EMG). 14 healthy age-matched controls underwent one session of sEMG acquisition to collect normative data.
Detailed description
This single-blind RCT with two parallel group was conducted according to the tenets of the Declaration of Helsinki, the guidelines for Good Clinical practice, and the Consolidated Standards of Reporting Trials (CONSORT).
Target population was chronic post-stroke patients who attend to the Neurorehabilitation Unit (AOUI Verona) where they were assessed for eligibility.
Who satisfied inclusion and exclusion criteria were randomly allocated in one of two groups, experimental group ad control group. Each patient, underwent BoNT injection in the paretic limb. The dose of BoNT injected into the target muscle was based on the severity of spasticity in each case. Different commercial formulations of BoNT were used according to the pharmaceutical portfolio contracts of our Hospital (Onabotulinumtoxin A, Abobotulinumtoxin A and Incobotulinumtoxin A). The dose, volume and number of injection sites were set accordingly. A Logiq ® Book XP portable ultrasound system (GE Healthcare; Chalfont St. Giles, UK) was used to inject BoNT into the target muscle.
Prior of the start of the study authors designed the experimental and the control group protocols. Two physiotherapists, one for each group carried out the rehabilitation procedures. Patients of both groups received 10 individual sessions (45 min/session, 2 sessions/week, five consecutive weeks). Treatments were performed in the rehabilitative gym of the G.B. Rossi University Hospital Neurological Rehabilitation Unit.
A subgroup of patients in the experimental group were investigated by Electromyography during the "hand-to-mouth" motor task (ARAT sub-item). The subject seated in a comfortable position on a chair with backrest, the feet resting on the floor and the knees and hips flexed at 90°. The start position consisted of the hand of the examined side lying on the distal third of the thigh. Then, the patient was asked to touch his mouth with the palm of the hand at normal speed and return to the starting position. The patient was instructed not move the head toward the hand. No other indications regarding how to move the arm for not to influence the spontaneity of the movement.
The EMG activity of 5 upper limb muscles of the affected side (deltoid scapular, deltoid clavicular, pectoralis major - clavicular head, triceps brachii, biceps brachii) was measured using pairs of self-adhesive surface electrodes. Disposable Ag-AgCl electrodes were placed according to SENIAM guidelines with an inter-electrode spacing of 0.02 m. Before electrode placement, the skin was shaved with a disposable, single-use razor and cleaned with alcohol.28 Raw EMG signals were collected using BTS FREEEMG 300 wireless surface EMG sensors (BTS spa, Milan, Italy) at a sampling rate of 1000 Hz. Raw EMG signals were processed with a customized routine developed in MATLAB environment (MathWorks, USA). The raw EMG signal was bandpass filtered at 20-450 Hz and then smoothed using a 20- ms root mean square (RMS) algorithm to obtain the envelope. Signals were recorded in three conditions: 30 s during resting position (basal), 5 s of maximal voluntary isometric contraction(MVIC), and during the hand-to-mouth task.
The "hand-to-mouth" task was divided into two sub-phases through the definition of three time-events: 1) start of the movement, 2) the moment when the hand touches the mouth and 3) return to the initial position. The first sub-phase, named "elbow flexion phase", was defined as the interval between the movement onset and the maximum elbow flexion. The second sub-phase, named "return phase", refers to the interval between the maximum elbow flexion until movement offset after returning to the starting position (Figure X). Normative data were collected from 14 healthy age-matched controls undergoing one EMGs acquisition. The time-events were determined using an accelerometer (BTS spa, Milan, Italy).
For the statistical analysis an intention to treat was used. Descriptive statistics included means, standard deviation and graphs. The Shapiro-Wilk test was used to test data distribution. Parametric or non-parametric tests were used for inferential statistics, accordingly. The T-Test for unpaired data (or the Mann-Whitney test) was used for testing between-group differences at T0 and T1. For this purpose, we computed the changes of score (Δ) between T0-T1. The T-Test for paired data (or Wilcoxon signed rank tests) was used to compare within-group changes over time. The level of significance was set p<0.05. Software statistics SPSS 20.0 (IBM SPSS Statistics for Windows, Version 20.0, Armonk, NY, USA).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
- Model description
- Single-blind RCT with two parallel group
| Arm | Type | Receives |
|---|---|---|
| Experimental group | Experimental | Device: Experimental group - robot assisted arm training (Armotion®)The experimental group was treated using a robot assisted arm training, Armotion (Reha Technology, Olten, Switzerland). |
| Control group | Active comparator | Other: Control group - conventional treatmentThe control group was treated using a conventional training, without end effector robot. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- age > 18 years;
- diagnosis of ischemic or hemorrhagic first-ever stroke as documented by a computerized tomography scan or magnetic resonance imaging;
- at least 6 months since stroke;
- Modified Ashworth Scale (MAS) score (shoulder and elbow) ≤ 3 and ≥1+;
- BoNT injection within the previous 12 weeks of at least one of muscles of the affected upper limb;
Key exclusion criteria (4 listed)
- any type of rehabilitation intervention in the 3 months prior to recruitment;
- bilateral cerebrovascular lesion;
- severe neuropsychologic impairment (global aphasia, severe attention deficit or neglect);
- concomitant orthopedic disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Experimental group - robot assisted arm training (Armotion®)Also: Robot assisted treatment (Armotion®)Passive mobilization and stretching exercises for affected upper limb (10 minutes) followed by robot-assisted exercises (35 minutes). Were selected four types of exercises contained within the Armotion® software: * "Collect the coins" * "Drive the car" * "Wash the dishes" * "Burst the balloons" For increment the difficulty, we have varied the assisted and non-assisted modality, increasing the number of repetitions over the study period. | Device | Experimental group |
| Control group - conventional treatmentAlso: Conventional treatmentUpper limb passive mobilization and stretching (10 minutes) followed by exercises (35 minutes) that incorporated single or multi-joints movements for the scapula, shoulder and elbow, performed in different positions (i.e. supine and standing position). The increase of difficulty and progression of intensity were obtained by increasing ROM, repetitions and performing movements against gravity or against slight resistance. | Other | Control group |
Primary outcome
Fugl Meyer Upper Limb Assessment scale
Time frame: Up to six weeks
Evaluate functional improvements of upper limbs
4 secondary outcomes
Modified Ashworth Scale
Time frame: Up to six weeks
Medical Research Council Scale
Time frame: Up to six weeks
Active Range of Motion
Time frame: Up to six weeks
UL electromyographic analysis of muscle activation
Time frame: Up to six weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jul 2018.
- Derived from this study: PubMed 30766508Gandolfi M, Vale N, Dimitrova EK, Mazzoleni S, Battini E, Filippetti M, Picelli A, Santamato A, Gravina M, Saltuari L, Smania N. Effectiveness of Robot-Assisted Upper Limb Training on Spasticity, Function and Muscle Activity in Chronic Stroke Patients Treated With Botulinum Toxin: A Randomized Single-Blinded Controlled Trial. Front Neurol. 2019 Jan 31;10:41. doi: 10.3389/fneur.2019.00041. eCollection 2019.
- Individual participant dataSharing planned: Undecided
Related trials for Stroke
Recruiting
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
Stroke, Acute
RecruitingPhase 4
Xeomin® and Gait Related Mobility After Stroke
Stroke
RecruitingObservational study
Implementing Transcranial Direct Current Stimulation in a Rehabilitation Setting
Aphasia, Stroke
Not yet recruiting
EEG Feedback-Based Vagus Nerve Stimulation for Post-Stroke Dysphagia
Ischemic Stroke, Post-stroke Dysphagia
RecruitingObservational study
Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
Moyamoya Disease, Moyamoya Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicola Smania, Professor principal investigator
Universita di Verona
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Experimental group - robot assisted arm training (Armotion®) in people with Stroke, run by Universita di Verona at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jul 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fugl Meyer Upper Limb Assessment scale (time frame: Up to six weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03590314, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jul 2018.